vs
Martin Marietta Materials（MLM）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
Martin Marietta Materials的季度营收约是UNITED THERAPEUTICS Corp的1.7倍（$1.4B vs $790.2M），Martin Marietta Materials净利率更高（111.1% vs 46.1%，领先65.0%），Martin Marietta Materials同比增速更快（17.0% vs 7.4%），过去两年UNITED THERAPEUTICS Corp的营收复合增速更高（8.0% vs -12.1%）
马丁·玛丽埃塔材料公司是美国大型集料及重型建筑材料供应商，业务覆盖美国26个州、加拿大及加勒比地区，主要为道路、人行道、地基等各类基建项目提供所需原材料。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
MLM vs UTHR — 直观对比
营收规模更大
MLM
是对方的1.7倍
$790.2M
营收增速更快
MLM
高出9.6%
7.4%
净利率更高
MLM
高出65.0%
46.1%
两年增速更快
UTHR
近两年复合增速
-12.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $790.2M |
| 净利润 | $1.5B | $364.3M |
| 毛利率 | 22.8% | 86.9% |
| 营业利润率 | 11.9% | 45.1% |
| 净利率 | 111.1% | 46.1% |
| 营收同比 | 17.0% | 7.4% |
| 净利润同比 | — | 20.9% |
| 每股收益（稀释后） | — | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLMUTHR
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.1B | $790.2M | ||
| Q3 25 | $1.8B | $799.5M | ||
| Q2 25 | $1.8B | $798.6M | ||
| Q1 25 | $1.4B | $794.4M | ||
| Q4 24 | $1.6B | $735.9M | ||
| Q3 24 | $1.9B | $748.9M | ||
| Q2 24 | $1.8B | $714.9M |
净利润MLMUTHR
| Q1 26 | $1.5B | — | ||
| Q4 25 | $279.0M | $364.3M | ||
| Q3 25 | $414.0M | $338.7M | ||
| Q2 25 | $328.0M | $309.5M | ||
| Q1 25 | $116.0M | $322.2M | ||
| Q4 24 | $293.0M | $301.3M | ||
| Q3 24 | $363.0M | $309.1M | ||
| Q2 24 | $294.0M | $278.1M |
毛利率MLMUTHR
| Q1 26 | 22.8% | — | ||
| Q4 25 | 35.0% | 86.9% | ||
| Q3 25 | 33.1% | 87.4% | ||
| Q2 25 | 30.0% | 89.0% | ||
| Q1 25 | 24.8% | 88.4% | ||
| Q4 24 | 30.0% | 89.7% | ||
| Q3 24 | 31.7% | 88.9% | ||
| Q2 24 | 29.3% | 89.1% |
营业利润率MLMUTHR
| Q1 26 | 11.9% | — | ||
| Q4 25 | 24.6% | 45.1% | ||
| Q3 25 | 27.4% | 48.6% | ||
| Q2 25 | 25.3% | 45.6% | ||
| Q1 25 | 14.3% | 48.2% | ||
| Q4 24 | 24.4% | 48.6% | ||
| Q3 24 | 25.9% | 45.8% | ||
| Q2 24 | 22.6% | 44.7% |
净利率MLMUTHR
| Q1 26 | 111.1% | — | ||
| Q4 25 | 24.5% | 46.1% | ||
| Q3 25 | 22.4% | 42.4% | ||
| Q2 25 | 18.1% | 38.8% | ||
| Q1 25 | 8.6% | 40.6% | ||
| Q4 24 | 18.0% | 40.9% | ||
| Q3 24 | 19.2% | 41.3% | ||
| Q2 24 | 16.7% | 38.9% |
每股收益（稀释后）MLMUTHR
| Q1 26 | — | — | ||
| Q4 25 | $4.59 | $7.66 | ||
| Q3 25 | $6.85 | $7.16 | ||
| Q2 25 | $5.43 | $6.41 | ||
| Q1 25 | $1.90 | $6.63 | ||
| Q4 24 | $4.87 | $6.23 | ||
| Q3 24 | $5.91 | $6.39 | ||
| Q2 24 | $4.76 | $5.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $273.0M | $2.9B |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $11.3B | $7.1B |
| 总资产 | $20.5B | $7.9B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资MLMUTHR
| Q1 26 | $273.0M | — | ||
| Q4 25 | $67.0M | $2.9B | ||
| Q3 25 | $57.0M | $2.8B | ||
| Q2 25 | $225.0M | $3.0B | ||
| Q1 25 | $101.0M | $3.3B | ||
| Q4 24 | $670.0M | $3.3B | ||
| Q3 24 | $52.0M | $3.3B | ||
| Q2 24 | $109.0M | $3.0B |
总债务MLMUTHR
| Q1 26 | $0 | — | ||
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.5B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $5.4B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.3B | — |
股东权益MLMUTHR
| Q1 26 | $11.3B | — | ||
| Q4 25 | $10.0B | $7.1B | ||
| Q3 25 | $9.7B | $6.6B | ||
| Q2 25 | $9.4B | $7.2B | ||
| Q1 25 | $9.1B | $6.8B | ||
| Q4 24 | $9.5B | $6.4B | ||
| Q3 24 | $9.2B | $6.1B | ||
| Q2 24 | $8.8B | $5.7B |
总资产MLMUTHR
| Q1 26 | $20.5B | — | ||
| Q4 25 | $18.7B | $7.9B | ||
| Q3 25 | $18.7B | $7.4B | ||
| Q2 25 | $18.1B | $7.9B | ||
| Q1 25 | $17.7B | $7.7B | ||
| Q4 24 | $18.2B | $7.4B | ||
| Q3 24 | $16.5B | $7.1B | ||
| Q2 24 | $16.3B | $6.7B |
负债/权益比MLMUTHR
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.53× | — | ||
| Q3 25 | 0.57× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $227.0M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | — | $173.3M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | 40.4% | 21.9% |
| 现金转化率经营现金流/净利润 | 0.15× | 0.95× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流MLMUTHR
| Q1 26 | $227.0M | — | ||
| Q4 25 | $629.0M | $346.2M | ||
| Q3 25 | $551.0M | $562.1M | ||
| Q2 25 | $387.0M | $191.7M | ||
| Q1 25 | $218.0M | $461.2M | ||
| Q4 24 | $686.0M | $341.2M | ||
| Q3 24 | $600.0M | $377.2M | ||
| Q2 24 | $1.0M | $232.2M |
自由现金流MLMUTHR
| Q1 26 | — | — | ||
| Q4 25 | $424.0M | $173.3M | ||
| Q3 25 | $361.0M | $351.6M | ||
| Q2 25 | $208.0M | $129.5M | ||
| Q1 25 | $-15.0M | $386.3M | ||
| Q4 24 | $453.0M | $254.5M | ||
| Q3 24 | $317.0M | $300.7M | ||
| Q2 24 | $-138.0M | $187.1M |
自由现金流率MLMUTHR
| Q1 26 | — | — | ||
| Q4 25 | 37.2% | 21.9% | ||
| Q3 25 | 19.6% | 44.0% | ||
| Q2 25 | 11.5% | 16.2% | ||
| Q1 25 | -1.1% | 48.6% | ||
| Q4 24 | 27.8% | 34.6% | ||
| Q3 24 | 16.8% | 40.2% | ||
| Q2 24 | -7.8% | 26.2% |
资本支出强度MLMUTHR
| Q1 26 | 40.4% | — | ||
| Q4 25 | 18.0% | 21.9% | ||
| Q3 25 | 10.3% | 26.3% | ||
| Q2 25 | 9.9% | 7.8% | ||
| Q1 25 | 17.2% | 9.4% | ||
| Q4 24 | 14.3% | 11.8% | ||
| Q3 24 | 15.0% | 10.2% | ||
| Q2 24 | 7.9% | 6.3% |
现金转化率MLMUTHR
| Q1 26 | 0.15× | — | ||
| Q4 25 | 2.25× | 0.95× | ||
| Q3 25 | 1.33× | 1.66× | ||
| Q2 25 | 1.18× | 0.62× | ||
| Q1 25 | 1.88× | 1.43× | ||
| Q4 24 | 2.34× | 1.13× | ||
| Q3 24 | 1.65× | 1.22× | ||
| Q2 24 | 0.00× | 0.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLM
暂无分部数据
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
